Venus Concept Inc.

Venus Concept Inc.

VERO
Venus Concept Inc.US flagNASDAQ Global Market
0.31
USD
+0.01
- -
578,187.00Market Cap
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
TTM
Revenue per Share
1,850.1
1,675.08
7,141.85
1,621.57
2,138.91
351.45
319.97
248.89
140.36
98.23
49.73
Basic EPS, GAAP
-2,466.55
-2,345.75
-5,983.23
-2,121.57
-786.92
-368.09
-69.72
-109.32
-68.47
-71.21
-46.13
Free Cash Flow per Basic Share
-2,638.68
-1,861.59
-6,534.21
-2,193.87
-788.83
-130.38
-61.45
-68.33
-23.85
-16.95
-17.52
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-13,400.52
-15,746.27
-55,158.95
-14,269.5
-1,465.81
-708.94
-546.44
-560.53
-481.39
-467.98
-300.27
Tangible Book Value per Share
-13,121.98
-15,413.29
4,424.55
116.84
520.94
112.16
79.38
-7.96
-40.25
-3.23
0.64
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
Sales/Revenue/Turnover
17
16
21
22
110
78
106
99
76
65
59
Operating Margin (%)
-119.12
-121.36
-81.15
-117.99
-27.42
-51.85
-16.61
-35.05
-37.08
-41.93
-59
Depreciation Expense
1
1
1
1
2
5
5
4
4
4
4
Net Income, GAAP
-23
-22
-18
-29
-41
-82
-23
-44
-37
-47
-55
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-133.32
-140.04
-83.78
-130.83
-36.79
-104.73
-21.79
-43.92
-48.79
-72.49
-92.76
Working Capital
20
5
18
20
52
83
76
44
35
18
-5
LT Debt
20
13
5
19
61
80
77
74
74
33
6
Total Equity
-122
-144
13
2
77
44
42
9
-13
3
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Mar'25
Jun'25
Sep'25
ST Debt
15
20
26
LT Borrowings
22
16
5
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
2
2
Market Capitalization
2
2
3

Working Capital

FRC

in mil. unless spec.
Mar'25
Jun'25
Sep'25
Total Current Assets
46
45
46
Cash, Cash Equivalents & STI
3
4
4
Accounts Receivable, Net
17
16
17
Inventories
18
16
16
Total Current Liabilities
36
41
51
Payables & Accruals
19
20
22
ST Debt
15
20
26
Deferred Revenue
2
2
2

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-100.38%
-121.1%
Free Cash Flow
- -
-18.09%
-13.76%
Net Income, GAAP
- -
26.12%
26.16%
Sales/Revenue/Turnover
- -
-7.62%
-15.09%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
21
20
18
18
76
2024
17
17
15
16
65
2025
14
16
14
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-20.36
-14.9
-18.05
- -
-68.47
2024
-16.92
-33.51
-13.1
-11.23
-71.21
2025
-17.44
-8.03
-12.14
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Rajiv Kanishka Liyanaarchchie De Silva
Full Time Employees
292
Sector
Healthcare
Industry
Medical - Devices
Address
235 Yorkland Boulevard Toronto ON Canada M2J 4Y8
IPO Date
Oct 12, 2017
Business
Venus Concept Inc. stands as a medical technology enterprise engaged in the development, global commercialization, and delivery of sophisticated minimally invasive and non-invasive technologies for medical aesthetics and hair restoration, alongside associated services, spanning both the United States and international markets. Its extensive product line encompasses a variety of aesthetic device platforms, including the Venus Legacy, a non-invasive system applied in dermatological and general surgical procedures particularly for women; Venus Versa and Venus Versa Pro, versatile multi-application devices utilized in a range of aesthetic and cosmetic treatments; and Venus Viva and Venus Viva MD, advanced, portable fractional radiofrequency systems designed for dermatological procedures necessitating skin ablation and resurfacing. The company also offers Venus Fiore, a device delivering non-thermal radiofrequency, massage, and magnetic field pulses for various medical indications; Venus Bliss and Venus Bliss Max, engineered for non-invasive lipolysis of the abdomen, flanks, back, and thighs in individuals with a body mass index of 30 or less; and Venus Glow, a motorized dermabrasion device for enhancing skin appearance. Furthermore, its portfolio includes NeoGraft, an advanced automated follicular unit extraction (FUE) and implantation system for hair restoration, and the ARTAS iX, a robotic system assisting practitioners in identifying, extracting, and implanting hair follicles during transplantation, as well as creating recipient sites. Recent innovations include the Venus NOVA, a multi-application platform for non-invasive body and skin treatments, including solutions for skin laxity, and AI.ME, an interactive, image-guided, computer-assisted system for fractional skin resurfacing. For hair removal and permanent hair reduction, including treating pseudofolliculitis barbae, Venus Concept provides Venus Velocity and Venus Epileve. The company maintains its corporate headquarters in Toronto, Canada.

Company News

APIChat
  • Venus Concept Announces Senior Management Changes

  • Venus Concept Announces Completion of Common Stock Sale and Short-Form Merger

  • Venus Concept Inc. (NASDAQ:VERO) Sees Significant Drop in Short Interest

  • Venus Concept Announces Intention to Voluntary Delist from Nasdaq and Deregister with SEC

  • Top 3 Health Care Stocks You May Want To Dump In January

  • Venus Concept Stock Explodes Over 500% After Major Investor Takes Control

  • Venus Concept Inc. (NASDAQ:VERO) Short Interest Down 35.0% in December

  • Sensus Healthcare (NASDAQ:SRTS) vs. Venus Concept (NASDAQ:VERO) Head-To-Head Comparison

  • Venus Concept Inc. (VERO) Q3 2025 Earnings Call Transcript

  • Venus Concept Announces Third Quarter 2025 Financial Results

  • Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction

  • Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

  • Cellulite Treatment Market Size to Reach USD 5.19 Billion by 2032, Driven by Rising Demand for Non-Invasive Aesthetic Solutions | S&S Insider

  • Venus Concept Inc. (VERO) Q2 2025 Earnings Call Transcript

  • Venus Concept Announces Second Quarter 2025 Financial Results

  • Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

  • Venus Concept Announces $6.5 Million Debt-to-Equity Exchange Transaction

  • Venus Concept Announces Closing of Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  • Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

  • Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million